MedTrace Logo

Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars

NCT03935594 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2023-01-09

Study results available
· View outcomes & findings →

Summary

Hypertrophic burn scars are experienced by more than 70% of burn victims. They are a major source of decreased quality of life in burn patients due to pain, decreased range of motion, and poor cosmetic appearance. Current treatment strategies (including fat grafting and laser resurfacing) are either highly invasive, prohibitively costly, or painful. Autologous Platelet Rich Plasma (PRP) does not require anesthesia, and is an inexpensive, safe, fast, and less painful alternative that has been recognized for its role in reducing scars associated with acne, among other things. While PRP has not been studied specifically in burn scars, there is sufficient theoretical and practical evidence that it will improve the appearance and feel of these debilitating scars, representing a large potential benefit for these patients with minimal associated risk.

Conditions

  • Hypertrophic Scar

Interventions

BIOLOGICAL

PRP Injection

1mL platelet rich plasma will be injected into each 1cm x 1cm area of scar tissue of the experimental half of the scar.

DRUG

Saline Injection

1mL NS will be injected into each 1cm x 1cm area of scar tissue of the control half of the scar.

Sponsors & Collaborators

  • Vanderbilt University Medical Center

    lead OTHER

Principal Investigators

  • Galen Perdikis, MD · Vanderbilt University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-18
Primary Completion
2021-05-24
Completion
2022-10-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03935594 on ClinicalTrials.gov